• Loss of $4.1M for the half-year, compared to a profit of $0.5M in the prior period
• Significant progress in clinical development of lead candidates bisantrene and RC220
• Received $2.8M R&D tax incentive payment from the Australian government

Racura Oncology Ltd (formerly Race Oncology Ltd) reported a loss of $4.1M for the half-year ended 31 December 2025, compared to a profit of $0.5M in the prior corresponding period. The loss was primarily due to increased research and development expenses, as well as share-based payment expenses and a loss on extinguishment of liabilities. During the period, the company made significant progress in the clinical development of its lead candidates. Key highlights include:- Publication of the Phase 1b/2 trial of bisantrene in the British Journal of Haematology- Presentation of data on the mechanism of action of (E,E)-bisantrene at the European Society for Medical Oncology Congress 2025- Expansion of the clinical program for RC220 with the initiation of new trials in acute myeloid leukaemia and non-small cell lung cancerThe company also received $2.8M in R&D tax incentive payments from the Australian government for the 2025 financial year, strengthening its cash position to $20.9M as at 31 December 2025.Subsequent to the end of the half-year, the company issued additional shares following the exercise of options, and announced a shares buy-back subject to shareholder approval.

The company did not provide any high-importance, price-sensitive forward-looking financial metrics or guidance.

The company did not provide any forward-looking outlook statements.